FindTrial
Sign In

Long-term quality of life and prognosis comparison between antrum-preserving double tract reconstruction of jejunal interposition procedure and traditional digestive reconstruction in proximal gastrectomy for adenocarcinoma of the esophagogastric junction: a prospective randomized controlled trial

Long-term quality of life and prognosis comparison between antrum-preserving double tract reconstruction of jejunal interposition procedure and traditional digestive reconstruction in proximal gastrectomy for adenocarcinoma of the esophagogastric junction: a prospective randomized controlled trial

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13004004
Enrollment
Unknown
Registered
2013-10-14
Start date
2014-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Group A:Esophagogastric anastomosis reconstruction
Group B:Roux-en-Y Reconstruction
Group C:Antrum-preserving double tract reconstruction of jejunal interposition

Sponsors

Affiliated Hospital of North Sichuan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 70; Gastroscopy: 2. tumor locate at the gastroesophageal junction (Seiwert I, II, III); 3. Pathological diagnosis of adenocarcinoma; 4. CXR/CT, abdominal ultrasound/CT exclude metastasis; 5. Resectable tumor; 6. No history of previous gastrointestinal surgery; 7. Good cardiopulmnoary functions; 8. Expectation survival period more than 6 months; 9. Karnofsky score more than 70 while Zubrod-ECOG-WHO score beyond 2; 10. WBC > 3.5*10^9/ml, PLT> 10*10^9/ml, T-Bil 50ml/min; 11. Patients included in this trail must be informed; 12. No other relevant diseases (ex: tumors in other sites or serious disease heart or central nervous system, CNS).

Exclusion criteria

Exclusion criteria: 1. Benign neoplasm of stomach; 2. Past history or excisting other malignancy; 3. MRI/EBUS/ CT suggest unresectable tumors; 4. Difficulty in endure anesthesia and surgery; 5. Uncontroled underlying diseases (unstable angina etc.); 6. Previous history of immunosuppresive therapy (including corticosteroids therapy), cytotoxic chemotherapy or radiotherapy; 7. Serious uncontroled infections or serious allergy history; 8. Diseases of CNS or psyche which affect congnition including CNS metastasis; 9. Serious pulmonary heart disease such as: acute myocardial infarction shorter than 6 months or congestive heart failure or symptomatic angina, coagulative function abnormal etc.

Design outcomes

Primary

MeasureTime frame
5-years surivival rate and OS;3-year DFS;Operation related mortality and compliaction relation;Operation time, intraoperational blood loss, postope;—

Countries

China

Contacts

Public ContactJiangwei Xiao

Affiliated Hospital of North Sichuan Medical College

nsmc2012@163.com+86 13890868466

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026